bioRxiv Science⌕ Search

Biology subjects

Callahan, W. S.

Publications and source records attributed to Callahan, W. S..

2 recordsLinked to original sources

Naegleria amoebae seek confinement and crawl persistently through narrow spaces

The "brain-eating amoeba" Naegleria fowleri dwells in ponds where it normally feeds on bacteria, but if it enters the brain it can cause a deadly infection. To establish infection, N. fowleri must migrate through different environments--along olfactory axons, through openings in the cribriform plate, and within brain tissue--yet how it does so remains unknown. As a model for N. fowleri migration within these environments, we examine how its non-pathogenic relative, Naegleria gruberi, navigates environments of distinct geometries. We show that Naegleria uses both actin-rich protrusions and membrane blebs to crawl across or between flat surfaces. We also explore how Naegleria interact with narrow channels and find that, unlike Dictyostelium amoebae that we show frequently disengage from channel interfaces, Naegleria amoebae probe channels until they enter. Once inside, Naegleria crawls quickly (>50 m/min) and unidirectionally over long distances (>1 mm) using only bleb-based motility. We also introduced Naegleria to granular hydrogel matrices that mimic pond sediments and found that cells readily enter and migrate through these three-dimensional matrices using both blebs and lamellar protrusions. Although cells in matrices showed lower persistence at short timescales, longer time scales correlate with increased persistence, suggesting Naegleria cells may retain memory of past orientation. We propose that pond life may select for three behaviors that prime Naegleria for pathogenesis: memory-guided motility that would facilitate exploration of sinus cavities, confinement-seeking ("claustrophilia") that would promote entry into narrow passages along olfactory axons, and persistent bleb-based migration that would allow rapid transit along axons to the brain.

cell biology↗

AAV gene therapy for Cockayne syndrome

Cockayne Syndrome (CS) is an autosomal recessive, progressive developmental and neurodegenerative disease. Approximately 30% of cases are caused by mutations in the ERCC8/CSA gene. Patients with CS present with cutaneous photosensitivity, growth failure, shorter life span and a progressive degeneration of the central nervous system. Loss of function mutations in CSA result in deficiencies in transcription-coupled nucleotide excision repair, regulation of RNA Pol II mediated transcription repair of oxidative DNA damage, and mitochondrial metabolism. Currently there are no available therapies for these patients. AAV gene therapy offers an opportunity to address this unmet need. We designed a new AAV vector encoding human CSA under a CBA promoter. We tested the therapeutic efficacy of this AAV9-CSA vector by neonatal ICV injection in the Csa-/-;Xpa-/- mouse model. Treatment with AAV9-CSA resulted in a significant increase in lifespan, and broad distribution of human CSA in the brain and heart. Despite clear therapeutic benefit, we also observed neuroradiological abnormalities, neuropathologic alterations including hypo-myelination, astrocytosis, microgliosis, and likely life limiting transcriptomic alterations in liver at endpoint. Nonetheless, the success of these experiments paves the way for the first in human clinical translation of a gene therapy for CS patients.

neuroscience↗